This is a preview of subscription content, log in via an institution to check access.
Reference
van de Laar C, et al. Cost-Effectiveness of a Jak1/Jak2-Inhibitor vs. a Biologic Disease-Modifying Antirheumatic Drug in a Treat-to-Target Strategy for Rheumatoid Arthritis. 20th Annual Congress of the European League Against Rheumatism : abstr. OP0313, 12 Jun 2019. Available from: URL: http://scientific.sparx-ip.net/archiveeular/index.cfm?c=a&view=2&item=2019OP0313
Rights and permissions
About this article
Cite this article
Baricitinib good choice in a treat-to-target strategy for RA. PharmacoEcon Outcomes News 831, 7 (2019). https://doi.org/10.1007/s40274-019-5995-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5995-2